



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 20 May 2016 (#14)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01) ([NOT-RM-16-014](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Collaborative Centers (U54) ([NOT-RM-16-015](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Research Grants (U01) ([NOT-RM-16-016](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Collaborative Centers (U54) ([NOT-RM-16-017](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Administrative Coordinating Center (U24) ([NOT-RM-16-018](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Informatics Network (U24) ([NOT-RM-16-019](#))
- **Remember to Account for Rigor and Reproducibility in Your Next Grant Application** - In the Research Strategy section of your application, you will need to show that you've critically evaluated the scientific premise and rigor of your research, as well as considered sex and other relevant biological variables. For example, in order to propose to study only one sex, you must first provide strong justification from scientific literature, preliminary data, or other relevant considerations.
- In an **Authentication of Key Biological and/or Chemical Resources** attachment within the Other Research Plan section of your application. Knowing how much validation is necessary is an inexact science, but for key reagents or resources that are essential to the success of the project, more is definitely better than less. Even in the case of commercially available reagents, a manufacturer's data sheet may not provide sufficient validation.

1. Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: ([PAR-16-215](#))

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This funding opportunity announcement (FOA) encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Applications submitted to this FOA should propose to develop, validate, and/or calibrate outcome measures, surrogate markers, and biomarkers in model organisms that can inform and effectively translate to human clinical trials for individuals with intellectual and developmental disabilities (IDD). In addition, applications may propose to conduct rigorous, controlled and standardized preclinical animal trials designed for safety, toxicity, and efficacy prediction or to perform an independent validation of efficacy in animals prior to human clinical trials. The goal of this FOA is to accelerate and improve the preclinical testing of candidate treatments and therapeutic compounds in order to move promising new drug therapies into clinical trials. Potential applicants may also be interested in the FOA [PAR-16-216](#), "Outcome Measures For Use In Treatment Trials of Individuals with Intellectual and Developmental Disabilities."

Budget: Budgets for direct costs of up to \$499,999 per year may be requested. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

2. Outcome Measures for Use in Treatment Trials of Individuals with Intellectual and Developmental Disabilities

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-216\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA "Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)."

Budget: Budgets for direct costs of up to \$499,999 per year may be requested for a maximum of \$2,499,996 direct costs over a five-year project period. The total project may not exceed 5 years.

3. Research Answers to NCI's Pediatric Provocative Questions

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-217\)](#)
[\(PAR-16-218\)](#)

Type: R21
R01

Application Due Date: June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM local time of applicant organization.

Aids application due dates: November 15, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI's Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list

Budget: R21-The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Application budgets must reflect the actual needs of the proposed project. R01-Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Impact of Aging in Human Cell Models of Alzheimer's Disease

Letter of Intent due date: August 28, 2016

Hyperlink: [\(RFA-AG-17-009\)](#)

Type: R01

Application Due Date: September 28, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The goal of this FOA is to establish the impact of aging on the expression and/or modulation of AD pathological processes and to assess age-related AD genotype-phenotype relationships in human cell models. Research incorporating different brain cell types to promote neural circuit maturation and complexity in such cell models is expected to better recapitulate and give greater insight into AD pathological processes.

Budget: Application budgets need to reflect the actual needs of the proposed project and should be limited to no more than \$250,000 direct cost per year. The total project for an application submitted in response to this FOA may not exceed five years

5. From Association to Function in the Alzheimers Disease Post Genomics Era

Letter of Intent due date: August 27, 2016

Hyperlink: [\(RFA-AG-17-010\)](#)
[\(RFA-AG-17-011\)](#)

Type: R01
R21

Application Due Date: September 27, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) solicits innovative and collaborative research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimer's disease (AD). Specifically, NIA is interested in identifying and developing more effective and integrated platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants prior to any in-depth mechanistic studies. The program encourages collaborative research projects that will translate initial GWAS discovery into functional and phenotypical insights and ultimately lead to understand the complex biology of AD.

Budget: R01 -NIA intends to commit \$4,000,000 in FY2017 to support 6-8 awards in response to this FOA. Application budgets need to reflect the actual needs of the proposed project and should be limited to no more than \$350,000 in direct costs per year. The total project for an application submitted in response to this FOA may not exceed five years. R21 - NIA intends to commit \$1,000,000 in FY2017 to support 4 awards in response to this FOA. The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year

6. Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research

Letter of Intent due date: July 2, 2016

Hyperlink: [\(RFA-AI-16-039\)](#)
[\(RFA-AI-16-040\)](#)

Type: R01
U01

Application Due Date: August 2, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (R01). The purpose of the opportunities under the revision application is to increase the number of underrepresented scientists (for this FOA, defined as Black South Africans at South African historically disadvantaged institutions (HDIs) and other Universities of Technology) engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.

Budget: Issuing IC and partner components intend to commit an estimated total of \$3 million per year to fund 10-15 awards in FY 2017 for applications in response to these FOA's R01 Application budgets are limited to \$200,000 per year in total costs for up to two years. A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted at South African institutions. Applicants may request support for up to 2 years. At the time of award of the revision, there must be two years remaining on the parent award for a two year revision request or one year remaining on the parent award for a one year revision request. Awards will be made as revisions to the parent R01 or U01 and cannot exceed the project period of the parent award.

7. Prescription Drug Abuse

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-16-232\)](#)
[\(PA-16-233\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.

Budget: R21 - Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

8. Mechanisms Mediating Osteoarthritis in Aging

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-16-239\)](#)
[\(PA-16-240\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites applications intended to encourage and accelerate the characterization of new or underutilized models and the testing of hypotheses that will lead to an improved understanding of the mechanisms of initiation and progression of osteoarthritis and the role of aging in the process. R21(The NIH Exploratory/Developmental Grant) supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on the field of study.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years. R21 - Application budgets are limited to no more than \$275,000 direct cost for two years of funding, and need to reflect actual needs of the proposed project.

9. Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-243\)](#)
[\(PA-16-244\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. This research opportunity encourages studies that address diverse scientific areas such as 1) pathogenesis, 2) host response, 3) disease transmission, 4) vector biology and natural history, 5) vaccines, 6) diagnostics, and 7) therapeutics.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

10. Gene Fusions in Pediatric Sarcomas

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-16-251\)](#)
[\(PA-16-252\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics. R21 = the exploratory/developmental research grant utilize the mechanism to foster cancer etiology and epidemiology research. While these studies may involve considerable risk, they may also lead to a breakthrough in a particular area, and to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, or clinical).

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year.

11. Accelerating the Pace of Drug Abuse Research Using Existing Data

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-234\)](#)

Type: R01

Application Due Date: [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

Budget: Budgets are limited to under \$500,000 direct costs per year and must reflect the actual needs of the proposed project. The maximum period is 5 years.

12. Dissemination and Implementation Research in Health

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-238\)](#)
[\(PAR-16-236\)](#)
[\(PAR-16-237\)](#)

Type: R01
R21
R03

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Budget: R01 – Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 – The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R03 - Application budgets are limited to \$50,000 in direct costs per year. The proposed project period must not exceed 2 years.

13. Bioengineering Research Grants (BRG)

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-242\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 5 years depending on the policy of each NIH Institute. Applicants are encouraged to review the current funding policy of each NIH Institute.

14. Neural Regulation of Cancer

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-245\)](#)
[\(PAR-16-246\)](#)

Type: R01
R21

Application Due Date: October 26, 2016; February 22, 2017; June 27, 2017; October 26, 2017; February 22, 2018; June 27, 2018; October 27, 2018; February 22, 2019; June 27, 2019, Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 5 years depending on the policy of each NIH Institute. Applicants are encouraged to review the current funding policy of each NIH Institute. R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

15. Building Evidence: Effective Palliative/End of Life Care Interventions

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-250\)](#)

Type: R01

Application Due Date: October 10, 2016; June 9, 2017; October 9, 2017; June 11, 2018; October 8, 2018; June 10, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This funding opportunity announcement (FOA) seeks to stimulate research that tests optimal end-of-life and palliative care (EOLPC) interventions/models of care that are based on individual- and family-centered outcomes. The testing of EOLPC interventions and models of care are urgently needed that address racial, ethnic and/or cultural diversity in children and adults for those with serious, advanced illness. Trials are needed to test efficacy and effectiveness of these interventions and/or models of care.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 5 years depending on the policy of each NIH Institute. Applicants are encouraged to review the current funding policy of each NIH Institute.

16. Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Tuberculosis Vaccine Design

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-254\)](#)

Type: R01

Application Due Date: September 6, 2016; September 6, 2017; September 6, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 5 years depending on the policy of each NIH Institute. Applicants are encouraged to review the current funding policy of each NIH Institute.

17. Cancer-related Behavioral Research through Integrating Existing Data**Letter of Intent due date:** 30 days prior to the application due date**Hyperlink:** [\(PAR-16-256\)](#)
[\(PAR-16-255\)](#)**Type:** R01
R21

Application Due Date: February 15, 2017; June 15, 2017; February 15, 2018; June 15 2018; February 15, 2019; June 14, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites applications that seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. The goal is to encourage applications that incorporate Integrative Data Analysis (IDA) methods to study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake. It is important that the data being integrated are from different sources and types (including both quantitative and qualitative; data may span different levels such as genetic and environmental) and should include at least one source of behavioral data. Importantly, applicants should use existing data sources rather than collect new data. In addition, creating harmonized measures, developing culturally sensitive measures, replicating results and cross-study comparisons will be encouraged.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 5 years. R21 -Direct costs are limited to \$275,000 over an two-year period, with no more than \$200,000 in direct costs allowed in any single year.

18. Predicting Behavioral Responses to Population-Level Cancer Control Strategies**Letter of Intent due date:** 30 days prior to the application due date**Hyperlink:** [\(PAR-16-257\)](#)**Type:** R21

Application Due Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018; April 11, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.

Budget: Direct costs are limited to \$275,000 over an two-year period, with no more than \$200,000 in direct costs allowed in any single year.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director’s Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P01 – Research Program Projects: For the support of a broadly based, multidisciplinary, often long-term research program which has a specific major objective or a basic theme. A program project generally involves the organized efforts of relatively large groups, members of which are conducting research projects designed to elucidate the various aspects or components of this objective. Each research project is usually under the leadership of an established investigator. The grant can provide support for certain basic resources used by these groups in the program, including clinical components, the sharing of which facilitates the total research effort. A program project is directed toward a range of problems having a central research focus, in contrast to the usually narrower thrust of the traditional research project. Each project supported through this mechanism should contribute or be directly related to the common theme of the total research effort. These scientifically meritorious projects should demonstrate an essential element of unity and interdependence, i.e., a system of research activities and projects directed toward a well-defined research program goal.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA	Funding Opportunity Announcement
PA	Program Announcements (<i>click on “PA” to search for further funding opportunities</i>)
RFA	Request for Applications (<i>click on “RFA” to search for further funding opportunities</i>)

Complete [Glossary and acronym list of NIH Terms](#)

